PGPIPN
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
PGPIPN is a milk-derived hexapeptide — not a skincare peptide. It came through the same source directory as the rest of this cosmetic-topical peptide family, but doesn’t actually belong to the cosmetic-skincare story; it’s documented here only for completeness, with an honest “this isn’t what it looks like” note.
What does it do in my body?
The public profile (graded Emerging, 3 studies, 0 human) describes preclinical anti-cancer and immune-modulation work: inhibiting ovarian-cancer cell invasion and growth in vitro and in vivo via MTA1/NM23H1 and BCL2 pathways.
How can it help me?
- Where the science stands: Emerging: 3 preclinical studies, 0 human
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
No adverse-effect data was captured in the source profile beyond the preclinical anti-cancer/immune-modulation research context. Safety is graded pending, not the “green” default of the genuinely topical-cosmetic members of this cluster.
Regulatory status: Not a cosmetic ingredient. This is a preclinical research compound, not FDA-reviewed and not sold through cosmetic or peptide-vendor channels per the captured source material.
Typical dosing
Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.
No topical or cosmetic use case exists for PGPIPN. No dosing or protocol information relevant to a skincare/cosmetic context was captured in the source material.
What should I avoid combining — and what's synergistic?
PGPIPN doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
How can I buy this?
We don't have a verified affiliate source for PGPIPN yet, so there's no coupon or vendor link here — we won't point you to a seller we haven't vetted. When buying any research-use-only peptide, the single biggest variable is the supply chain: insist on a vendor that publishes third-party Certificates of Analysis (COAs) confirming identity and >99% purity. Working with a peptide-literate clinician is one solid route — see our provider directory — or check back as our verified sources list grows.
Not actually a skincare peptide — a milk-derived hexapeptide from preclinical anti-cancer research that landed in a cosmetic directory by category drift. Documented here for completeness, with the same honest “this isn’t what it looks like” note the source material gives it.
| Class | Not a topical cosmetic peptide — a milk-derived research compound, mis-filed into the cosmetic-peptide directory |
| Mechanism (one line) | Preclinical: inhibits ovarian-cancer cell invasion and growth in vitro and in vivo via MTA1/NM23H1 and BCL2 pathways |
| Evidence base | Emerging: 3 preclinical studies, 0 human |
| Safety record | Safety: pending |
| Regulatory status | Research compound, not a cosmetic ingredient and not FDA-reviewed |
What it is
PGPIPN is a milk-derived hexapeptide — not a skincare peptide. It came through the same source directory as the rest of this cosmetic-topical peptide family, but doesn’t actually belong to the cosmetic-skincare story; it’s documented here only for completeness, with an honest “this isn’t what it looks like” note.
How it works
The public profile (graded Emerging, 3 studies, 0 human) describes preclinical anti-cancer and immune-modulation work: inhibiting ovarian-cancer cell invasion and growth in vitro and in vivo via MTA1/NM23H1 and BCL2 pathways.
What the research shows
Graded Emerging on the public profile: 3 preclinical studies, 0 human trials, describing ovarian-cancer cell-invasion inhibition via the MTA1/NM23H1 and BCL2 pathways.
OHM’s internal 0035 categorization pass grades PGPIPN Tier D / pending / provisional with a SECONDARY heal-recover label and “minimal published human data”.
Status: an immune/oncology research peptide that landed in a cosmetic list by category drift — included here only so the cluster migration is complete. This is not skincare content and should not be treated as one.
Real-world protocol
No topical or cosmetic use case exists for PGPIPN. No dosing or protocol information relevant to a skincare/cosmetic context was captured in the source material.
Side effects & management
No adverse-effect data was captured in the source profile beyond the preclinical anti-cancer/immune-modulation research context. Safety is graded pending, not the “green” default of the genuinely topical-cosmetic members of this cluster.
Regulatory status
Not a cosmetic ingredient. This is a preclinical research compound, not FDA-reviewed and not sold through cosmetic or peptide-vendor channels per the captured source material.
Sources
- (thepeptidelist.com directory, captured 2026-06-07) — profile grade: Emerging, 3 preclinical studies, 0 human. Describes MTA1/NM23H1 and BCL2 pathway ovarian-cancer research.
- OHM tier/safety grading: Tier D / pending / provisional, SECONDARY heal-recover, “minimal published human data.”
- Migrated from
cosmetic-topical-peptides-cluster.md(2026-06-10 cluster build) as part of the cluster-to-standalone-article migration — the source explicitly flags this compound as miscategorized into the cosmetic directory.
Sources & references
- (thepeptidelist.com directory, captured 2026-06-07) — profile grade: Emerging, 3 preclinical studies, 0 human. Describes MTA1/NM23H1 and BCL2 pathway ovarian-cancer research.
- OHM tier/safety grading: Tier D / pending / provisional, SECONDARY heal-recover, “minimal published human data.”
- Migrated from
cosmetic-topical-peptides-cluster.md(2026-06-10 cluster build) as part of the cluster-to-standalone-article migration — the source explicitly flags this compound as miscategorized into the cosmetic directory.